Summary & Overview
CPT 0283U: Versiti VWD Type 2B Evaluation, Plasma Assay
CPT code 0283U designates the Versiti™ VWD Type 2B Evaluation, a specialized plasma-based laboratory test that assesses platelet binding and von Willebrand factor multimer patterns to differentiate VWD Type 2B from other von Willebrand disease subtypes. Introduced effective October 1, 2021, the code captures a single-company diagnostic assay that has implications for accurate classification of a rare but clinically significant bleeding disorder. Nationally, precise coding of such assays matters for claim adjudication, coverage determinations, and tracking utilization of emerging or proprietary diagnostics.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, the typical laboratory setting where it is performed, and the potential payer landscape relevant to coverage and billing. The publication outlines coding context, effective date, and what to expect in payer interactions—such as the presence of a single-source proprietary assay—and summarizes areas where data were not provided.
This document is written for a national audience and is intended to inform billing staff, laboratory managers, and policy analysts about the code's clinical role, administrative classification, and the payer environment to consider when submitting or reviewing claims related to specialized VWD diagnostic testing.
Billing Code Overview
CPT code 0283U is a laboratory assay code established for the Versiti™ VWD Type 2B Evaluation performed by Versiti™ Diagnostic Laboratories on a plasma specimen. The test evaluates platelet binding and multimer levels to differentiate subtypes of von Willebrand disease (VWD) Type 2B, supporting diagnostic classification and management decisions.
Service type: Laboratory diagnostic test — specialized coagulation/hematology assay
Typical site of service: Independent diagnostic laboratory or hospital laboratory that receives plasma specimens
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old woman with a history of easy bruising, mucosal bleeding, and a family history of von Willebrand disease is referred to a hematology clinic. Prior screening tests show low von Willebrand factor antigen and abnormal ristocetin cofactor activity with suspected qualitative VWF abnormality. The clinician orders the Versiti™ VWD Type 2B Evaluation (0283U) on a plasma specimen to assess platelet binding and VWF multimer distribution to differentiate Type 2B VWD from other VWD subtypes and platelet-type (pseudo) von Willebrand disease. Blood is drawn in the outpatient phlebotomy area or specialty laboratory, labeled, and shipped to Versiti™ Diagnostic Laboratories under required specimen handling conditions. Results are reviewed by the hematologist; findings of enhanced platelet binding and loss of high-molecular-weight multimers support a diagnosis of Type 2B VWD and guide management decisions such as avoiding platelet-activating therapies, considering desmopressin testing responses, and perioperative hemostatic planning. Typical sites of service include outpatient specialty hematology clinics, hospital outpatient labs, and reference laboratory collection centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when only the interpreting physician's professional component is billed separately from the technical lab work (rare for reference lab send-outs). |